News Drug price controversies hit pharma's reputation Patient groups slam pharma over drug costs in latest survey.
News Valeant's Siliq approved but suicidal thoughts warning will ... But drug will have boxed warning over suicidal ideation.
News Despite Trump price concerns, JP Morgan event anticipates M&... 2017 could be a bumper year for M&A - but Trump's price control threats dominate
News Valeant exec and Philidor chief charged with multi-million d... Two charged with massive deception and fraud - but Valeant escapes censure so far
News Valeant could sell gastro drug unit to Takeda Valeant may sell Salix and other units to pay off debts.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.